Shareholders Foundation, Inc.

Immunomedics, Inc. (NASDAQ:IMMU) Investor Alert: Investigation of Potential Securities Laws Violations

An investigation for investors in Immunomedics, Inc. (NASDAQ:IMMU) shares over potential securities laws violations by Immunomedics was announced and NASDAQ:IMMU stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com

 
Repost This

San Diego, CA -- (SBWIRE) -- 01/28/2014 -- An investigation on behalf of investors of Immunomedics, Inc. (NASDAQ:IMMU) shares over potential securities laws violations by Immunomedics and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of Immunomedics, Inc. (NASDAQ:IMMU) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Immunomedics, Inc. (NASDAQ:IMMU) concerning whether a series of statements Immunomedics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Immunomedics, Inc. reported that its Total Revenue declined from $32.73 million for the 12 months period that ended on June 30, 2012 to $4.96 million for the 12 months period that ended on June 30, 2013 and that over the respective time periods its Net income of $0.81 million declined to a Net Loss of $12.17 million.

Shares of Immunomedics, Inc. (NASDAQ:IMMU) grew from $2.29 per share in March 2013 to $7.141 on October 2, 2013.

Then on October 9, 2013, Immunomedics, Inc. announced that the Company has received notification from Takeda Pharmaceutical Company of the termination of the licensing agreement signed between Nycomed GmbH and I Immunomedics, Inc. for the worldwide rights to veltuzumab, the humanized anti-CD20 antibody, for all non-cancer indications.

Shares of Immunomedics, Inc. declined from over $7 per share in early October 2013 to as low as $3.42 per share in early November 2013.

On January 27, 2014, NASDAQ:IMMU shares closed at $4.99 per share.

Those who purchased shares of Immunomedics, Inc. (NASDAQ:IMMU), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com